CPT-Pharmacometrics & Systems Pharmacology

Article	Citations
Issue Information	46
Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population	43
Issue Information	43
Evaluation of covariate effects in item response theory models	36
Pharmacometric and statistical considerations for dose optimization	32
Issue Information	30
Correction to Network module‐based drug repositioning for pulmonary arterial hypertension	29
Issue Information	29
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients	28
Building Hybrid Pharmacometric‐Machine Learning Models in Oncology Drug Development: Current State and Recommendations	27
Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP‐1	27
A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach	26
Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential	25
Enhance Multistate Models With Clinically Meaningful Graphs	24
Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation	24
Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates	24
Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease	24
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist	23
Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story	23
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy	22
Issue Information	22
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children	22
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach	22
Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval	21
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies	21

Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models	21
Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery	21
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models	21
Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report	21
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations	19
Impact of Mechanistic Modeling and Simulation Methodologies on Product‐Specific Guidance Development for Non‐Orally Administered Drug Products	18
Update to improve reproducibility and interpretability: A response to “Machine Learning for Tumor Growth Inhibition”	18
Shap‐Cov: An Explainable Machine Learning Based Workflow for Rapid Covariate Identification in Population Modeling	18
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II	18
Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients	17
Using Virtual Patients to Evaluate Dosing Strategies for Bispecifics With a Bell‐Shaped Efficacy Curve	17
Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin	17
Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham	17
Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women	16
Quantitative systems toxicology modeling in pharmaceutical research and development: An industry‐wide survey and selected case study examples	16
Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution	16
Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine	16
Regulatory utility of physiologically‐based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report	15
Issue Information	15
Tutorial for Modeling Delays in Biological Systems in the NONMEM Software	15
The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens	15
Mechanistic pharmacokinetic–pharmacodynamic modeling and simulations of naloxone auto‐injector 10 mg reversal of opioid‐induced respiratory depression	15
The interaction of core modules as a basis for elucidating network behavior determining Parkinson's disease pathogenesis	15
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration	15
Tutorial on model selection and validation of model input into precision dosing software for model‐informed precision dosing	15
Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials	15
Modeling of Disease Progression of Type 2 Diabetes Using Real‐World Data: Quantifying Competing Risks of Morbidity and Mortality	14
A physiologically‐based pharmacokinetic modeling approach for dosing amiodarone in children on ECMO	14
	14
Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions	14
	14
CYTOCON: The manually curated database of human in vivo cell and molecule concentrations	13
Flexible and efficient Bayesian pharmacometrics modeling using Stan and Torsten, Part I	13
Population Pharmacokinetics and Transfer of Gabapentin When Used as a Pain Adjunct for Cesarean Deliveries	13
Variable or variate? A conundrum in pharmacometrics exposure–response models	13
Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact	13
A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection	13
Longitudinal and time‐to‐event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma	13
Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin	13
	12
	12
Activity and perspective on quantitative modeling and simulation in Japan: Update from the Pharmaceuticals and Medical Devices Agency	12
	12
Physiologically based pharmacokinetic modeling of drug–drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy	12
Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles	12
Issue Information	12
Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials	12
	12
Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases	11
Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B	11

Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss–Newton Method	11
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager g	11
Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview	11
Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus	11
Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps	11
A Model‐Based Approach to Evaluate Anti‐Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T‐Cell Bispecific Cibisatamab	11
Issue Information	11
Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling	11
PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?	10
A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling	10
The influence of flip‐flop in population pharmacokinetic analyses	10
Low‐dimensional neural ordinary differential equations accounting for inter‐individual variability implemented in Monolix and NONMEM	10
Quantitative Systems Toxicology Modeling of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended‐Release and Immediate‐Release Formulations in Adults With Chronic Alcohol	10
Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non‐small cell lung cancer based on bintrafusp alfa trials	10
Quantitative systems pharmacology in the age of artificial intelligence	10
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates	10
Issue Information	10
Predicting Residual 21‐Hydroxylase Enzymatic Activity in Pediatric and Adult Congenital Adrenal Hyperplasia Patients: Towards Individualized Therapy	10
Population pharmacokinetic modeling of zavegepant, a calcitonin gene‐related peptide receptor antagonist, in healthy adults and patients with migraine	10
Evaluation of the Drug–Drug Interaction Potential of the GlyT1 Inhibitor Iclepertin (BI 425809): A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach	10
Quantitative system pharmacology as a legitimate approach to examine extrapolation strategies used to support pediatric drug development	10
Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer	10
Item performance of the scale for the assessment and rating of ataxia in rare and ultra‐rare genetic ataxias	10
Development of and insights from systems pharmacology models of antibody‐drug conjugates	10
Type 1 diabetes prevention clinical trial simulator: Case reports of model‐informed drug development tool	10
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases	10
Issue Information	10
Mid‐dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients	10
State‐of‐the‐Art on Model‐Informed Drug Development Approaches for Pediatric Rare Diseases	10
Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach	9
Population model‐based analysis of the memory B‐cell response following belimumab therapy in the treatment of systemic lupus erythematosus	9
Within‐chain parallelization—Giving Stan Jet Fuel for population modeling in pharmacometrics	9
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it?	9
Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example	9
Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma	9
Machine Learning‐Based Model Selection and Averaging Outperform Single‐Model Approaches for a Priori Vancomycin Precision Dosing	9
	9
Semimechanistic modeling of copeptin and aldosterone kinetics and dynamics in response to rehydration treatment for diabetic ketoacidosis in children	9
Issue Information	9
Issue Information	9
	9
Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application	9
Predicting the correct dose in children: Role of computational Pediatric Physiological‐based pharmacokinetics modeling tools	9
Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin	9
Semi‐Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre‐Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)	9
Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model	9
Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target‐mediated drug disposition and OATP1B3‐mediated hepatic uptake in a physiologically based model	9
Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody	9
A Pharmacometric Workflow for Resolving Model Instability in Model Use‐Reuse Settings	9
Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections	9
Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19	9
Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients	9
Quantitative approaches to drug safety: The 2022 PSP special issue	9
Moving From Point‐Based Analysis to Systems‐Based Modeling: Knowledge Integration to Address Antimicrobial Resistance	9
Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach	9
Population pharmacokinetic modeling of oral brepocitinib in healthy volunteers and patients with immuno‐inflammatory diseases	9
A literature review of drug transport mechanisms during lactation	9
The area under the effect curve as an efficacy determinant for anti‐infectives	8
Development and comparison of model‐integrated evidence approaches for bioequivalence studies with pharmacokinetic end points	8
Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors	8
Isavuconazole and Calcium Channel Blocker for Invasive Fungal Disease Accompanied With Hypertension: Evidence From the FAERS and PBPK/PD Model	8
Predicting disease activity in patients with multiple sclerosis: An explainable machine‐learning approach in the Mavenclad trials	8
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling	8
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans	8
Issue Information	8
Response to “Enhance Multistate Models With Clinically Meaningful Graphs”	8
Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?	8
Application of Physiologically‐Based Pharmacokinetic Modeling to Support Drug Labeling: Prediction of CYP3A4 ‐Mediated Pirtobrutinib‐Drug Interaction	8
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer	8
Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective	8
Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study	8
QPRapp: A Web‐Based Platform for PK/PD Simulations and Early Feasibility Analysis	8
Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit	7
Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma	7
	7
Applying interpretable machine learning workflow to evaluate exposure–response relationships for large‐molecule oncology drugs	7
Abstracts	7
Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data	7
Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm	7
A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug‐induced toxicity	7

Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis	7
A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population	7
A fully automatic tool for development of population pharmacokinetic models	7
	7
Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers	7
Synthetic Model Combination: A new machine‐learning method for pharmacometric model ensembling	7
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug	7
A multi‐model approach to predict efficacious clinical dose for an anti‐TGF‐β antibody (GC2008) in the treatment of osteogenesis imperfecta	7
	7
Delineating gene–environment effects using virtual twins of patients treated with clozapine	7
Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer	7
Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201	7
Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis	7
Issue Information	7
Translating in vitro CFTR rescue into small molecule correctors for cystic fibrosis using the Library of Integrated Network‐based Cellular Signatures drug discovery platform	7
Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Patients With Advanced Solid Tumors	7
Deep compartment models: A deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling	7
Mechanistic modeling of drug products applied to the skin: A workshop summary report	7
Quantitative systems pharmacology model of α‐synuclein pathology in Parkinson's disease‐like mouse for investigation of passive immunotherapy mechanisms	7
Evaluation and Mitigation of Time‐Dependent Confounding Effects in Conventional Exposure‐Response Analyses for Oncology Drugs	7
Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision‐Making	7
Growth‐rate model predicts in vivo tumor response from in vitro data	6
In memoriam Lambertus (“Bert”) A. Peletier 29 March 1937–16 December 2023: Furthering quantitative pharmacology through applied mathematics	6
From In Vitro Efficacy to Long‐Term HbA1c Response for GLP‐1R/GlucagonR Agonism Using the 4GI‐HbA1c Systems Model	6
Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical‐driven balance of population average and variability	6
Quantitative methods and modeling to assess COVID‐19‐interrupted in vivo pharmacokinetic bioequivalence studies with two reference batches	6
Mixed‐effects models and the drug titration paradox	6
Physiologically‐based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency	6
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development	6
Multistate modeling for survival analysis in critically ill patients treated with meropenem	6
Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis	6
Skipping a pillar does not make for strong foundations: Pharmacokinetic‐pharmacodynamic reasoning behind the shape of dose–response relationships in oncology	6
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis	6
Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups	6
Corrigendum to: 2022 WCoP Abstracts	6
A Model‐Based Meta‐Analysis of Pembrolizumab Effects on Patient‐Reported Quality of Life: Advancing Patient‐Centered Oncology Drug Development	6
A continued learning approach for model‐informed precision dosing: Updating models in clinical practice	6
Virtual Clinical Trial Reveals Significant Clinical Potential of Targeting Tumor‐Associated Macrophages and Microglia to Treat Glioblastoma	6
Developmental pharmacokinetics of indomethacin in preterm neonates: Severely decreased drug clearance in the first week of life	6
Issue Information	6
Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody	6
Issue Information	6
Mechanistic modeling of ophthalmic, nasal, injectable, and implant generic drug products: A workshop summary report	6
Population Pharmacokinetic Model of Pegbing in Healthy Subjects and Chronic Hepatitis B Patients	6
Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV	6
Issue Information	6
Increasing impact of quantitative methods and modeling in establishment of bioequivalence and characterization of drug delivery	5
Introduction of an artificial neural network–based method for concentration‐time predictions	5
Evaluation of machine learning methods for covariate data imputation in pharmacometrics	5
A network paradigm predicts drug synergistic effects using downstream protein–protein interactions	5
	5
Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV‐2 patients	5
Effect of Cumulative Exposure on the Efficacy of Paroxetine: A Population Pharmacokinetic‐Pharmacodynamic and Machine Learning Analyses	5
Pediatric model‐based dose optimization using a pooled exposure–response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma	5
Preclinical side effect prediction through pathway engineering of protein interaction network models	5
Application of longitudinal item response theory models to modeling Parkinson’s disease progression	5
PBPK perspective on alternative CYP3A4 inducers for rifampin	5
Biased computation of probability of target attainment for antimicrobial drugs	5
	5
Population Pharmacokinetics and Exposure‐Response Relationship of Hemoporfin in Pediatric Patients With Port‐Wine Stain	5
Model enhanced reinforcement learning to enable precision dosing: A theoretical case study with dosing of propofol	5
Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator	5
PBPK Modeling to Predict Clinical Drug–Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F‐Hydroxypropylamide	5
Consistent methods for fat‐free mass, creatinine clearance, and glomerular filtration rate to describe renal function from neonates to adults	5
Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine	5
Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat	5
Development and application of a PBPK modeling strategy to support antimalarial drug development	5
Machine learning for tumor growth inhibition: Interpretable predictive models for transparency and reproducibility	5
Population Pharmacokinetic Modeling and Pediatric Exposure of Dexamethasone Sodium Phosphate Encapsulated in Erythrocytes (eDSP) Administered Monthly for Treatment of Neurological Symptoms of Patients	5
Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic	5
Hepatic OATP1B zonal distribution: Implications for rifampicin‐mediated drug–drug interactions explored within a PBPK framework	5
Computational design of clinical trials using a combination of simulation and the genetic algorithm	5
Population pharmacokinetic analysis of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in patients and healthy volunteers	5
	5
Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction	5
Disease Modeling and External Model Evaluation Through Clinical Data Sharing Platform for HR+/HER2− Breast Cancer	5
	5
Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19	5
A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC	5
Two new user‐friendly methods to assess pharmacometric parameter identifiability on categorical and continuous scales	5
Model‐based prediction of progression‐free survival for combination therapies in oncology	5
To be or not to be, when synthetic data meet clinical pharmacology: A focused study on pharmacogenetics	5
A Step‐by‐Step Workflow for Performing In Silico Clinical Trials With Nonlinear Mixed Effects Models	5
Minimal physiologically‐based hybrid model of pharmacokinetics in pregnant women: Application to antenatal corticosteroids	5
Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB‐02) in Patients With Advanced Solid Tumors	5
Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data	5
Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients	4
Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug–drug interaction predictions	4
Tumor growth inhibition modeling to support the starting dose for dacomitinib	4
Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of theDNAdamage response pathway	4
Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action	4
Construction of a prognostic model based on memory CD4+ T cell–associated genes for lung adenocarcinoma and its applications in immunotherapy	4
Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models	4
A Dose‐Aware Model for Revealing Dose‐Risk Relationship of Drug–Drug Interaction	4
Physiologically based pharmacokinetic modeling for dose optimization of quinine–phenobarbital coadministration in patients with cerebral malaria	4